Salute e Benessere
XENICAL Strengthens Market Position as Obesity Rates Surge Worldwide | DelveInsight
XENICAL (orlistat), developed by Genentech (a Roche subsidiary), is a powerful, specific, and reversible gastrointestinal lipase inhibitor. Orlistat acts as a reversible inhibitor of gastrointestinal lipases, working within the stomach and small intestine. It binds covalently to the active serine site of gastric and pancreatic lipases, rendering them inactive and preventing the breakdown of dietary triglycerides into absorbable free fatty acids and monoglycerides. This mechanism reduces fat absorption, leading to a caloric deficit that supports weight management. XENICAL is designed for oral use only.
It is approved for obesity management, including weight loss and long-term weight maintenance, when used alongside a calorie-controlled diet. Additionally, it helps reduce the risk of weight regain after initial weight loss. XENICAL is prescribed for obese patients with a BMI of at least 30 kg/m² or for overweight individuals (BMI ≥27 kg/m²) with risk factors such as hypertension, diabetes, or dyslipidemia, where weight loss may offer clinical benefits.
Learn more about XENICAL projected market size for obesity @
Obesity is the second leading cause of preventable death and is strongly associated with inflammatory conditions that contribute to numerous health issues, including cardiovascular disease, diabetes, respiratory disorders, psychological challenges, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. It has become a major public health crisis, worsening steadily over the past five decades.
The prevalence of obesity has increased among both children and adults across all genders and socioeconomic groups in developed and developing nations. In 2023, the total prevalent population of obesity in the United States was estimated at approximately cases, a number projected to rise further by 2034, according to DelveInsight.
Obesity management focuses on reducing body weight and fat percentage to lower associated health risks. Treatment strategies include dietary changes, exercise, behavioral therapy, lifestyle modifications, medications, and surgical interventions such as intragastric balloons, bariatric surgery, and laparoscopic gastric banding.
Despite the availability of FDA-approved obesity treatments, particularly pharmacotherapy, their usage remains limited due to factors such as insurance coverage, cost, safety concerns, and doubts about long-term effectiveness. Currently approved medications include Since obesity is not an immediately life-threatening condition, ensuring the safety of these medications remains a top priority.
Several pharmaceutical companies are actively developing new obesity treatments. The expected launch of potential therapies between 2024 and 2034 is likely to expand the market across the 7MM. Additionally, the development of disease-modifying treatment options is expected to reshape the obesity market dynamics in the coming years.
Discover more about the obesity market in detail @
Marketed competitors to XENICAL include and , both of which are GLP-1 receptor agonists that provide alternative approaches to weight management. SAXENDA (liraglutide) is approved for adults and, in certain cases, pediatric patients with obesity or overweight and comorbidities. It is used as an adjunct to a reduced-calorie diet and increased physical activity. Similarly, WEGOVY (semaglutide) is administered as a 2.4 mg injection for adults with obesity or overweight and is being further developed in an oral formulation. These agents offer innovative options by modulating appetite and metabolic pathways, expanding the treatment landscape beyond XENICAL's fat absorption inhibition mechanism.
are emerging obesity therapies with distinct mechanisms of action. Survodutide targets multiple metabolic pathways, while Orforglipron, an oral GLP-1 receptor agonist, offers convenient dosing with promising weight loss outcomes.
Another notable candidate in Eli Lilly obesity pipeline is , a triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. In a Phase II trial, retatrutide demonstrated a mean weight reduction of over 17.5% in adults without diabetes but with obesity or pre-obesity, marking a significant advancement in weight management therapies.
is also a potential competitor for XENICAL. Beyond CagriSema, Novo Nordisk is advancing , targeting dual gut hormones to amplify weight loss effects. These novel treatments aim to not only help patients shed excess weight but also improve metabolic health, reducing the risk of obesity-related conditions like diabetes and cardiovascular disease.
To know more about the number of competing drugs in development, visit @
In June 2004 , the original XENICAL patent was set to expire, signaling the end of its initial market exclusivity under the US patent system. However, recognizing its clinical importance and commercial potential, the US Patent and Trademark Office granted a five-year extension, prolonging patent protection until June 2009 .
When the patent finally expired in 2009, it allowed generic versions of orlistat to enter markets where patent protection was no longer in place, increasing competition and reducing prices. This process highlights the US patent system's balance—providing temporary exclusivity to reward innovation and protect investments while eventually ensuring broader access to essential medications.
Discover how XENICAL is shaping the presbyopia treatment landscape @
XENICAL is a weight management drug that effectively reduces weight and improves obesity-related conditions like . Its mechanism of action, which blocks fat absorption rather than suppressing appetite, provides an alternative for patients who cannot tolerate other weight-loss medications.
As , the market for weight management treatments expands, positioning XENICAL favorably with its long-term safety profile, non-systemic absorption, and (120 mg) and over-the-counter (60 mg as ALLI) forms. into combination therapies could enhance its effectiveness and broaden its clinical applications.
However, the —such as oily stools, flatulence, and fecal urgency—remain significant drawbacks, affecting patient adherence. Additionally, its when compared to newer anti-obesity drugs, and it requires strict dietary adherence to be most effective.
from newer weight-loss medications, like GLP-1 receptor agonists, which offer superior efficacy and better tolerability, challenges XENICAL's market position. for alternatives with fewer gastrointestinal side effects and better long-term adherence may also affect its continued use.
Dive deeper to get more insight into XENICAL's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key obesity companies, including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hypothalamic obesity companies such as among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key pediatric obesity companies such as among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/xenical-strengthens-market-position-as-obesity-rates-surge-worldwide--delveinsight-302425663.html